Search results
DYSPORT (abobotulinumtoxinA) for injection is indicated for the treatment of: • spasticity in patients 2 years of age and older • cervical dystonia in adults
- Dysport® Pediatric Spasticity Dosing & Administration Data
DYSPORT (abobotulinumtoxinA) for injection is indicated for...
- Dysport® Pediatric Spasticity Dosing & Administration Data
DYSPORT (abobotulinumtoxinA) for injection is indicated for the treatment of: spasticity in patients 2 years of age and older; cervical dystonia in adults
Dysport® Dosing in Pediatric Spasticity. Dysport efficacy and safety were established in clinical trials featuring the following FDA-approved dosing ranges1. Pediatric Upper Limb Spasticity (with a weight of at least 10 kg): 8 Units/kg to 16 Units/kg. Pediatric Lower Limb Spasticity: 10 Units/kg to 15 Units/kg. BICEPS. 3-6 Units/kg.
DYSPORT is indicated for the treatment of upper limb spasticity in pediatric patients 2 years of age and older, excluding spasticity caused by cerebral palsy. Lower Limb Spasticity in Pediatric Patients
Muscles for injection for lower limb spasticity in pediatric patients with their respective FDA-approved Dysport dose range. Total dose per treatment session must not exceed Dysport 15 Units/kg for unilateral lower limb injections, Dysport 30 Units/kg for bilateral injections, or Dysport 1000 Units, whichever is lower.
For the treatment of cervical dystonia, glabellar lines, and upper limb spasticity in adults, it is not known whether DYSPORT is safe or effective in children under 18 years of age. For the treatment of lower limb spasticity, it is not known whether DYSPORT is safe or effective in children under 2 years of age.
DYSPORT® is indicated for the treatment of lower limb spasticity in pediatric patients 2 years of age and older. 2 DOSAGE AND ADMINISTRATION 2.1 Instructions for Safe Use
